Antidiabetic Effect of Fenugreek Seed Powder Solution ( Trigonella foenum-graecum L.) on Hyperlipidemia in Diabetic Patients

Genet Alem Geberemeskel, Yared Godefa Debebe, Nigisty Abraha Nguse, Genet Alem Geberemeskel, Yared Godefa Debebe, Nigisty Abraha Nguse

Abstract

Background: Many drugs are commercially available for use in the management of diabetes. However, their side effects and high costs underscore the need for herbal alternative drugs. Trigonella foenum-graecum is one of the medicinal plants which are important in the management of diabetes mellitus. This study investigated the effect of Trigonella foenum-graecum seed powder solution on the lipid profile of newly diagnosed type II diabetic patients.

Methods: A total of N = 114 newly diagnosed type II diabetic patients without any significant diabetes complication were selected. They were grouped into two groups: the treatment group (n = 57) consumed 25 g Trigonella foenum-graecum seed powder solution orally twice a day for one month and the second group is the control (n = 57) which receives metformin. Blood sample was collected from each participant by a medical technologist/technician before and after the study. Lipid profile was analyzed by using Mindray BS 200E fully automated clinical chemistry analyzer.

Result: By the end of the intervention period, the treatment group showed significantly lower total cholesterol level by 13.6% as compared with the baseline level (219.1 ± 35.51 vs. 189.29 ± 29.06, P < 0.001) and the control group (189.29 ± 29.06 vs. 208.2 ± 40.2, P < 0.001); triglyceride level also reduced by 23.53% compared with the baseline level (256.1 ± 15.4 vs. 195.8 ± 82.95, P < 0.001) and compared with the control group (195.8 ± 82.95 vs. 244.1 ± 96.9, P < 0.05); and low-density lipoprotein cholesterol level also reduced by 23.4% as compared to the baseline level (137.9 ± 26.9 vs. 105.6 ± 24.2, P < 0.001) and the control group (between groups) (105.6 ± 24.2 vs. 144.1 ± 23.3, P < 0.001), but the treatment group showed significantly increased high-density lipoprotein cholesterol level by 21.7% as compared to the baseline level, within group (37.8 ± 1.51 vs. 48.3 ± 11.9, P < 0.001), and the control group, between groups (48.3 ± 11.9 vs. 36.01 ± 9.5, P < 0.001). However, lipid profile levels in the control group were not significantly changed.

Conclusion: The present study showed that the administration of Trigonella foenum-graecum seed powder solution had pronounced effects in improving lipid metabolism in type II diabetic patients with no adverse effects. Therefore, Trigonella foenum-graecum seed may provide new alternatives for the clinical management of type II diabetes.

Conflict of interest statement

The authors declare that they have no competing interests.

Copyright © 2019 Genet Alem Geberemeskel et al.

Figures

Figure 1
Figure 1
Flow chart describing the number of participants in the treatment and control groups who participated in the study. Dependent variable: primary end points: TC, TG, HDL-C, and LDL-C. Independent variable: the intervention variable was Trigonella foenum-graecum seed powder solution. Other covariants include age, sex, marital status, level of education, and occupational status.
Figure 2
Figure 2
TC level of the treatment and control groups on day 1 and day 30. ∗∗Indicates significant differences (P value ≤ 0.001), day 1 vs. day 30 treatment group. ∗∗Indicates significant difference (P value ≤ 0.001), treatment vs. control on day 30.
Figure 3
Figure 3
TG level of the treatment and control groups on day 1 and day 30. The results are expressed as mean ± SD. ∗∗Indicates significant differences (P value ≤ 0.001), day 1 vs. day 30 treatment group. ≠Indicates significant differences (P value ≤ 0.05), treatment group vs. control group on day 30.
Figure 4
Figure 4
HDL-C level of the treatment and control groups on day 1 and day 30. The results are expressed as mean ± SD. ∗∗Indicates significant differences (P value ≤ 0.001), day 1 vs. day 30 treatment group. ∗∗Indicates significant differences (P value ≤ 0.001), treatment group vs. control group on day30.
Figure 5
Figure 5
LDL-C level of the treatment and control groups on day 1 and day 30. The results are expressed as mean ± SD. ∗∗Indicates significant differences (P value ≤ 0.001), day 1 vs. day 30 treatment group. ∗∗Indicates significant differences (P value ≤ 0.001), treatment vs. control on day 30.

References

    1. Yibru E., Menon M., Belayneh Y., Seyifu D. The effect of Coriandrum sativum seed extract on hyperglycemia, lipid profile and renal function in streptozotocin induced type-2 diabetic Swiss albino mice. International Journal of Health Sciences and Research. 2015;5(7):166–177.
    1. Tadesse B. Antidiabetic activity and phytochemical screening of crude extracts of Stevia rebaudiana Bertoni and Ajuga remota Benth grown in Ethiopia on alloxan-induced diabetic mice (Doctoral dissertation, aau) AAU Institutional Repository; 2008.
    1. Assefa F. Effect of combined aerobic and resistance exercises on blood glucose level and risk factors in male type II diabetic patients residing in Haramaya University main campus and its surrounding (Doctoral dissertation) Haramaya University; 2013.
    1. Kumar K., Kumar S., Datta A., Bandyopadhyay A. Effect of fenugreek seeds on glycemia and dyslipidemia in patients with type 2 diabetes mellitus. International Journal of Medical Science and Public Health. 2015;4(7):997–1000. doi: 10.5455/ijmsph.2015.11032015202.
    1. World Health Organization. WHO Diabetes Fact Sheet No 312. 2013. .
    1. Kleefstra N., Houweling S. T., Bakker S. J. L., et al. Chromium treatment has no effect in patients with type 2 diabetes in a western population: a randomized, double-blind, placebo-controlled trial. Diabetes Care. 2007;30(5):1092–1096. doi: 10.2337/dc06-2192.
    1. Freshet A. Antidiabetic activity of Ajuga remota Benth (harmegusa) leaves in streptozotocin induced diabetic rats (Doctoral dissertation) AAU; 2013.
    1. International Diabetes Federation. The IDF Diabetes Atlas 5th Edition: a summary of the figures and key findings. 2013. .
    1. Ambachew Y., Kahsay S., Tesfay R., et al. Prevalence of diabetes mellitus among patients visiting medical outpatient department of Ayder Referral Hospital, Mekelle, Ethiopia: A three years pooled data. International Journal of Pharma Sciences and Research. 2015;6
    1. Adiels M., Olofsson S. O., Taskinen M. R., Borén J. Overproduction of very low–density lipoproteins is the hallmark of the dyslipidemia in the metabolic syndrome. Arteriosclerosis, Thrombosis, and Vascular Biology. 2008;28(7):1225–1236. doi: 10.1161/ATVBAHA.107.160192.
    1. Mohammadi S., Montasser Kouhsari S., Monavar Feshani A. Antidiabetic properties of the ethanolic extract of Rhus coriaria fruits in rats. Daru. 2010;18(4):270–275.
    1. American Diabetes Association. Standards of medical care in diabetes—2009. Diabetes Care. 2009;32(Supplement 1):S13–S61. doi: 10.2337/dc09-S013.
    1. Sauvaire Y., Petit P., Broca C., et al. 4-Hydroxyisoleucine: a novel amino acid potentiator of insulin secretion. Diabetes. 1998;47(2):206–210. doi: 10.2337/diab.47.2.206.
    1. Singh A. B., Tamarkar A. K., Shweta, Narender T., Srivastava A. K. Antihyperglycaemic effect of an unusual amino acid (4-hydroxyisoleucine) in C57BL/KsJ-db/db mice. Natural Product Research. 2010;24(3):258–265. doi: 10.1080/14786410902836693.
    1. Hannan J. M. A., Ali L., Rokeya B., et al. Soluble dietary fibre fraction of Trigonella foenum-graecum (fenugreek) seed improves glucose homeostasis in animal models of type 1 and type 2 diabetes by delaying carbohydrate digestion and absorption, and enhancing insulin action. British Journal of Nutrition. 2007;97(3):514–521. doi: 10.1017/S0007114507657869.
    1. Goyal S., Gupta N., Chatterjee S. Investigating therapeutic potential of Trigonella foenum-graecum L. as our defense mechanism against several human diseases. Journal of Toxicology. 2016;2016:10. doi: 10.1155/2016/1250387.1250387
    1. Roberts K. T. The potential of fenugreek (Trigonella foenum-graecum) as a functional food and nutraceutical and its effects on glycemia and lipidemia. Journal of Medicinal Food. 2011;14(12):1485–1489. doi: 10.1089/jmf.2011.0002.
    1. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) The Lancet. 1998;352(9131):837–853. doi: 10.1016/s0140-6736(98)07019-6.
    1. Kesari A. N., Gupta R. K., Watal G. Hypoglycemic effects of Murraya koenigii on normal and alloxan-diabetic rabbits. Journal of Ethnopharmacology. 2005;97(2):247–251. doi: 10.1016/j.jep.2004.11.006.
    1. Gupta A., Gupta R., Lal B. Effect of Trigonella foenum-graecum (fenugreek) seeds on glycaemic control and insulin resistance in type 2 diabetes mellitus: a double blind placebo controlled study. The Journal of the Association of Physicians of India. 2001;49:1057–1061.
    1. Dangi R. S., Lagu M. D., Choudhary L. B., Ranjekar P. K., Gupta V. S. Assessment of genetic diversity in Trigonella foenum-graecum and Trigonella caerulea using ISSR and RAPD markers. BMC Plant Biology. 2004;4(1):p. 13. doi: 10.1186/1471-2229-4-13.
    1. Campbell-Tofte J. I., Mølgaard P., Winther K. Harnessing the potential clinical use of medicinal plants as anti-diabetic agents. Botanics: Targets and Therapy. 2012;2:7–19. doi: 10.2147/btat.s17302.
    1. Prasanna M. Hypolipidemic effect of fenugreek: diabetic patients: A clinical study. Indian Journal of Pharmacology. 2000;32:34–36.
    1. Birhane G. Effect of processing on phytochemicals and nutrients composition of fenugreek (Trigonella foenum-graecum L.), and development of value added products (Doctoral dissertation) AAU; 2012.
    1. Meghwal M., Goswami T. K. A review on the functional properties, nutritional content, medicinal utilization and potential application of fenugreek. Journal of Food Processing & Technology. 2012;3(9) doi: 10.4172/2157-7110.1000181.
    1. Mitra A., Bhattacharya D. Dose-dependent effects of fenugreek composite in diabetes with dislipidaemia. Internet Journal of Food Safety. 2006;8:49–55.
    1. Lu F. R., Shen L., Qin Y., Gao L., Li H., Dai Y. Clinical observation on Trigonella foenum-graecum L. total saponins in combination with sulfonylureas in the treatment of type 2 diabetes mellitus. Chinese Journal of Integrative Medicine. 2008;14(1):56–60. doi: 10.1007/s11655-007-9005-3.
    1. Sharma R. D., Raghuram T. C. Hypoglycaemic effect of fenugreek seeds in non-insulin dependent diabetic subjects. Nutrition Research. 1990;10(7):731–739. doi: 10.1016/S0271-5317(05)80822-X.
    1. Renuka C., Ramesh N., Saravanan K. Evaluation of the antidiabetic effect of Trigonella foenum-graecum seed powder on alloxaninduced diabetic albino rats. International Journal of PharmTech Research. 2009;1(4):1580–1584.
    1. Kassaian N., Azadbakht L., Forghani B., Amini M. Effect of fenugreek seeds on blood glucose and lipid profiles in type 2 diabetic patients. International Journal for Vitamin and Nutrition Research. 2009;79(1):34–39. doi: 10.1024/0300-9831.79.1.34.
    1. Gaddam A., Galla C., Thummisetti S., Marikanty R. K., Palanisamy U. D., Rao P. V. Role of fenugreek in the prevention of type 2 diabetes mellitus in prediabetes. Journal of Diabetes & Metabolic Disorders. 2015;14(1):p. 1. doi: 10.1186/s40200-015-0208-4.

Source: PubMed

Szponzorok és közreműködők

Egészségi állapot

Kábítószer-beavatkozások

3
Iratkozz fel